ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Gastroenterology · Lancet · 2025-11-20

Phase 3 CASSANDRA trial, first randomisation, 260 patients with resectable or borderline resectable PDAC: preoperative PAXG gave longer median EFS than mFOLFIRINOX (16.0 vs 10.2 months; HR 0.63). Grade ≥3 adverse events: 66% vs 61%.

RCTn = 260
Reni et al. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.